posed that immunosuppression be individualized in relation to the patient's immunologic risk (2) .
By using a multicenter cohort of kidney and simultaneous kidney-pancreas (SPK) transplant recipients, we studied the association of single-nucleotide polymorphisms (SNPs) with AR. One of our initial observations was that the incidence of AR varied significantly by center. Such variation can result in associations at one center that cannot be validated at other sites. Therefore, we did our analyses using standard statistical methods and novel knowledge discovery methods that accounted for this center-to-center variation. We found that a number of SNPs were associated with AR. Defining SNPs associated with increased rejection risk will potentially allow for individualizing immunosuppression and to gain better insight into mechanisms of AR.
RESULTS

Baseline Characteristics and Outcomes
Nine hundred ninety kidney transplant recipients were enrolled from six transplant centers. The demographic and transplant-related characteristics for these recipients are listed in Table 1 . In the first year posttransplant, 181 (18%) recipients experienced AR and 177 (98%) were biopsy confirmed. However, the rate of AR varied across the six study centers: 12%, 30%, 15%, 14%, 0%, and 9% for center 1 to 6, respectively (PϽ0.0001). The median time to AR diagnosis was 33 days (range 7-364 days). The recipients' pathologists reported the following types of AR: 70% cellular, 18% antibody mediated, 10% with features of both, and 2% unknown. Treatment for AR was as follows: 52% steroids alone, 4% antibodies alone, 25% steroid and antibodies together, 12% steroids followed by antibodies, and 7% other.
SNPs Associated With AR
In a Cox proportional hazards model adjusted by recipient race only and stratified by transplant center, the top 15 SNPs that were associated with AR, all with P less than 0.05, are shown in Table 2 . (All SNPs genotyped are in Supplemental Digital Content 1, http://links.lww.com/TP/A297.) These The six transplant centers were University of Minnesota, Hennepin County Medical Center (Minneapolis, MN), Mayo Clinic (Rochester, MN), University of Iowa, University of Alabama, and University of Alberta.
a Missing data: living donor race status missing in 176 subjects, living donor gender missing in 2 subjects, delayed/slow allograft function missing in 92 subjects, cold ischemia time missing in 111 subjects, final PRA missing in 5 subjects, B-/T-cell crossmatch missing in 37 subjects, smoking status missing in 1 subject, prior nonkidney transplant missing in 44 subjects, and CMV recipient/donor status missing in 44 subjects.
HTN, hypertension; PRA, panel reactive antibody; Tx, transplantation; HLA, human leukocyte antigen; IL, interleukin; CNI, calcineurin inhibitor; SPK, simultaneous kidney-pancreas; CMV, cytomegalovirus.
simple models for the entire list of SNPs tested for association with AR are shown in Supplemental Digital Content 2 (http://links.lww.com/TP/A298). The SNPs are listed by increasing P values. Many of the top 15 SNPs such as rs2227931 in ATR, rs2267130 in CHEK2, rs3088142 in DUSP13 represent signaling pathways that play an important role in activation of T cells. The SNP in VANGL1 (rs4839469) was also associated with AR. In the multivariate model, similar SNPs remained as top SNPs associated with AR (Table 3) . In a multivariate model, the factors that were independently associated with AR were recipient factors (race, age, gender, and weight), panel reactive antibody presence, number of human leukocyte antigen mismatches, T-or B-cell crossmatch positive, antibody induction, type of calcineurin inhibitor used, steroid use at day 14 posttransplant, SPK transplant (vs. kidney transplant alone), cause of end-stage renal disease, living donor (vs. deceased donor), donor age, and transplant center. Given that transplant center was independently associated with AR even after accounting for these clinical factors, we analyzed the SNPs associated with AR, stratifying by transplant center. The multivariate models for the entire list of SNPs tested for association with AR are shown in Supplemental Digital Content 3 (http://links.lww.com/TP/A299). None of the SNPs were statistically significant, after accounting for false discovery rate (FDR) of 10%. In the analysis limited to acute cellular rejection only, similar SNPs were seen among the top 15 SNPs (footnote in Table 3 ).
SNPs Associated With AR Using Three Knowledge Discovery Methods
We determine combination of SNPs associated with AR. The 14 SNPs associated with AR as determined by all three methods are highlighted in Table 4 . None of these SNPs were ranked among the top 15 SNPs in the multivariate analysis as shown in Table 3 .
SNPs Associated With Severity of AR
Given the predominance of cellular rejection in our study population, we divided our cohort into three groups: no biopsy (nϭ609), t-score less than or equal to 1 (nϭ271), and t-score more than or equal to 2 (nϭ83). There were no tubulitis (t)-scores available for 27 patients from the local pathologist reading of the biopsy-confirmed AR. These 27 subjects were excluded from this analysis. The distribution of the t-scores on the remaining 154 patients' AR biopsies were as follows: 0 (17%), 1 (37%), 2 (32%), and 3 (14%). There were 200 patients with no AR, but had a kidney allograft biopsy, in a similar time frame posttransplant (no AR group with biopsy at median of 32 days and range 3 to 366 days vs. AR group with median 30 days and range of 7 to 364 days). The distribution of pathology t-scores in these 200 patients were as follows: 0 (89%), 1 (9%), 2 (2%), and 3 (Ͻ1%). In both groups, the t-scores were highly correlated with the i-scores (PϽ0.001, Fisher's exact test); therefore, the analysis was not repeated for the i-scores. The factors independently associated with severity of AR were transplant center (see Table, Supplemental Digital Content 4, http://links.lww.com/TP/A300), recipient race, recipient age, recipient gender, panel reactive antibody, number of human leukocyte antigen mismatches, donor age, type of calcineurin inhibitor use at baseline, recipient weight at the time of transplant, antibody induction, and smoking status. The SNPs associated with having more severe tubulitis scores (t-scoreՆ2 vs. t-scoreՅ1) are shown in Table 5 . One of these top 15 SNPs associated with severity of AR did overlap with the SNPs associated with AR namely rs6163 in CYP17A1 (Pϭ3.30ϫ10
Ϫ3
). The two SNPs most strongly associated with t-scores in this analysis were rs2228059 in IL15RA (Pϭ4.8ϫ10
Ϫ4
) and rs811925 in PRDM1 (Pϭ2.3ϫ10
). The entire list of SNPs tested for association with severity of AR is shown in Supplemental Digital Content 5 (http://links.lww.com/TP/A301). None of the SNPs were statistically significant, after accounting for FDR of 10%.
DISCUSSION
The goal of this study was to identify genetic variants associated with AR. However, we found significant center-tocenter variation in occurrence of AR among the study centers. Such center-to-center variation could explain why some SNPs associated with AR at one center may be difficult to validate at other centers. We also identified SNPs associated with AR using several methods including traditional statistical methods with stratification by transplant center. We also used novel knowledge discovery methods to identify potential SNP-SNP interactions after accounting for the centerto-center variation in occurrence of AR. These knowledge discovery methods allowed us to analyze each transplant center separately. The most strongly associated SNPs with AR were involved in signaling pathways genes such as rs2227931 in ATR, and rs3088142 in DUSP13. Such genes may play a role in T-cell activation. We also determined that different novel SNPs were associated with severity of t-scores on biopsy such as rs811925 in PRDM1 and rs2228059 in IL15RA. PRDM1 is involved in repressing the ␤-interferon (IFN) gene (3), whereas IL15RA is a high-affinity receptor for the inflammatory cytokine interleukin 15 (4).
Our study is the first to account for significant centerto-center variation in the occurrence of AR. Prior multicenter SNP studies have not accounted for center-to-center variation in AR (5, 6) . The most significant SNPs associated with AR in this study, ranked by P value, were predominantly in intracellular pathways that could activate T cells. These include SNPs in the rs2227931 in ATR, rs2267130 in CHEK2, and rs3088142 in DUSP13 genes. ATR is a critical checkpoint kinase that leads to phosphorylation of several proteins (7) . It is reasonable to assume that greater ATR activity could lead to cell activation during an immune response. Thus, the C allele of the coding synonymous SNP rs2227931 in ATR is associated with an increased risk of AR in this study, possibly by increasing ATR activity through splice variation. The CHEK2 is a critical checkpoint regulator in cell cycle replication. CHEK2 is activated by phosphorylation in response to DNA damage (8) . Thus, the C allele of the intronic SNP rs2267130 in CHEK2 is associated with decreased risk of AR, possibly by reducing the activity of CHEK2. DUSP13 is a member of a protein-tyrosine phosphatase superfamily that cooperates with protein kinases to regulate cell proliferation and differentiation (9) . The T allele of missense SNP rs3088142 in DUSP13 gene is associated with an increased risk of AR and probably leads to increased activity of DUSP13. The A allele of missense SNP rs4839469 in VANGL1 is associated with AR. VANGL1 is a novel protein because its mutations in this gene have been associated with neural tube defects (10), and VANGL1 is involved in tumor cell migration (11) . Its role in AR is not known. It is possible that other studies could find similar SNPs associated with AR, if they genotyped them in their cohort.
Previous studies have found other SNPs associated with AR namely ABCB1 gene haplotype (12) , ABCB1 2677T allele, IMPDH2 3757C allele and IL-10-592A (5), and IMPDH1 (rs2278293 and rs2278294) (13) . Other studies have also genotyped SNPs in 20 other genes that have provided conflicting associations with transplant outcomes (6). These genes had SNPs that were genotyped in this study but not found to be significantly associated with AR. It is possible that these SNPs are not associated with AR after accounting for the center-to-center variation or center-specific practices.
This study is the first to determine SNPs associated with severity of AR as determined by t-scores. It is well known that there is variation in the severity of AR (14) ; hence, it is not surprising that not all the same SNPs were associated with risk of AR and severity of tubulitis. This study describes the clinical and genetic factors that are associated with this variation in severity of AR by studying the severity of tubulitis on allograft biopsy. The PRDM1 gene encodes a protein that acts as a repressor of ␤-IFN gene expression. The protein binds specifically to the positive regulatory domain I element of the ␤-IFN gene promoter (15) . The C allele of the missense SNP rs811925 was associated with increased odds of a tubulitis score greater than or equal to 2 compared with t-score less than or equal to 1. (Table 5 ) Similarly, a missense SNP (rs2228059) in IL15RA, which is a high affinity cytokine receptor for the inflammatory cytokine interleukin 15, was seen to be associated with severity of tubulitis. This receptor is structurally related to IL2R-␣, the high-affinity receptor for IL2 (16) . In murine models, IL15 intraarticular injections induce a local tissue inflammatory infiltrate composed of predominantly T cells (4) ( Table 5) .
It is possible that the association of SNPs in some of the candidate genes was not seen in our study after accounting for multiple testing because of small effect sizes of these SNPs and limitations of sample size. We are planning on validating the SNPs shown in Tables 3 to 5 , in the subsequent 2000 kidney transplant recipients who are being enrolled by this study. We plan to genotype only the top SNPs from this study in this subsequent validation cohort. The number of SNPs that will be genotyped in the larger validation cohort will be determined by the number of AR events in the validation cohort. Because the validation cohort will need to account for multiple testing using a rigorous test, only a few top SNPs shown in Tables 3 to 5 will be eligible for genotyping in the validation cohort. The genes of those SNPs association that have an association in the validation cohort will need to be studied for The SNPs identified by three correlational-based feature selection methods, namely, best-first search, JRip, and decision trees a and a 10-fold crossvalidation.
b
The SNPs are shown with their specific ranking, from Table 3A and Supplemental Digital Content 3 (http://links.lww.com/TP/A299) in the multivariate model. a A final SNP set was created combining the SNPs found by the three knowledge discovery methods. These three methods included the best-first search procedure (23) . A second knowledge discovery method used a rule discovery tool named "JRip," which is based on a propositional rule learner, Repeated Incremental Pruning to Produce Error Reduction (24) . The SNPs in rules that classified for presence of AR were extracted into the final feature set. For the third knowledge discovery method, decision trees were constructed with J48, a tool that is analogous to C4.5 (26) and classification and regression tree analysis (25) . The SNPs (nodes) of pathways that resulted in positive outcome (presence of AR) were extracted to the final feature set. Duplicates were removed from the final set. Then by using a Cox proportional hazards model, we determined the association with AR for these SNPs, across all the transplant centers in the study and in both African Americans and non-African Americans.
b Each of the three knowledge discovery methods were conducted with 10-fold crossvalidation. In the 10-fold crossvalidation, the dataset was divided into 10 slices/folds, each of which preserves the distribution of the outcome of AR. There were a total of 10 runs, in which a fold was removed from the dataset and reserved for testing, and the remaining 9 folds are used for training, or discovering hypotheses (rules, trees, or features) that may explain AR. After the system was optimized on training, the resulting hypotheses were tested against the data in the testing set. The results (sensitivity, specificity, and predictive values) were calculated for each fold and then averaged over the 10 runs. The sensitivity across the runs ranged between 85% and 95%. We evaluated the resulting sets of features, rules, or trees on separate validation sets and found minimal evidence of overfitting, in that the sensitivity remained high on validation.
synon, synonymous; near-gene-5, variation within 2000 bases of 5Ј end of gene; SNP, single-nucleotide polymorphism; HR, hazards ratio; CI, confidence interval; AR, acute rejection.
gene expression in a future study. This study does not collect any samples for gene expression. Another potential limitation is that our t-and i-scores were not read by a central pathologist blinded to the clinical information. However, the central pathologist scores and local pathologist had similar rates of AR using the biopsy scores of t-score more than 1 and i-score more than 1 (McNemar's Test, Pϭ0.60, data not shown) (17) .
In summary, this study has described significant center-to-center variation in AR, which is a challenge especially for all multicenter, genomics study. This variation can explain the difficulty in validating SNPs or other genomics markers found in one center, in another center. We have analyzed SNPs associated with AR, accounting for this center-to-center variation. SNPs potentially involved in T-cell activation such as rs2227931 in ATR, CHEK2 (rs2267130), and DUSP13 (rs3088142) are novel findings in this study. This study is also unique for determining SNPs in PRDM1 (rs811925) and IL15RA (rs2228059), associated with severity of AR using biopsy scores. Our study will validate the top SNPs (Tables 3-5) in an ongoing, larger cohort of 2000 kidney transplant recipients after accounting for multitesting. In the future, with a larger cohort of recipients, this study may have enough power to conduct a genome-wide association study.
MATERIALS AND METHODS
Clinical Data
Between, October 3, 2005 and April 10, 2008, 990 kidney and SPK recipients at 6 transplant centers (Table 1) were enrolled in a prospective study of kidney allograft function. Patients were consented for participation at the time of or soon after transplantation. All kidney transplant recipients undergoing a kidney or SPK transplant were eligible. Patients with nonkidney solid-organ transplants were not eligible. The institutional review boards at each of the study sites approved this study.
Immunosuppression and AR treatment were center specific. Clinical data were collected at the time of transplant and regularly until allograft failure and maintained in a central database. Delayed graft function was defined as a need for dialysis in the first week posttransplantation. AR was defined by the treating physician. Local pathologist reading of biopsies was collected for all biopsies done for cause.
Genotyping
SNP genotyping was done primarily using a customized Affymetrix GeneChip having a total of 3404 SNP assays (18) on a Affymetrix GeneChip Scanner 3000 Targeted Genotyping System (Affymetrix, Santa Clara, CA) (19) . Additional variants were genotyped using the SNPlex (Applied Biosystems Inc, Foster City, CA) and Sequenom (Sequenom, Inc, San Diego, CA) platforms, as per manufacturer's recommendation. We selected SNPs for genotyping if they were known or believed to be functional within biologically relevant genes to transplantation and included genes in pathways associated with immunity, cell signaling, cell growth and proliferation, and drug absorption, disposition, metabolism, and excretion. In the absence of functional variants, intragenic tagging variants were selected. The design of this custom SNP chip has been described previously (18) .
Genotyping Quality Control
We assessed data quality using negative controls (water) and duplicate samples (3% on Affymetrix, 7% on SNPlex, and 1% on Sequenom). On the Affymetrix platform, we genotyped 31 individuals in duplicated with more than 99% concordance. For all platforms, we eliminated SNPs with concor- dance rates less than 90% and with call rates less than 60%. We genotyped 20 SNPs on multiple platforms and had a concordance rate of more than 97%, and SNP call rates were present for greater than 82% of the samples. SNPs that deviated from Hardy Weinberg equilibrium (PϽ1ϫ10 Ϫ6 ) were removed. SNPs were excluded from further analysis if the minor allele frequency was less than 5% in both the African American and non-African American population. In the final analysis, we included 2552 SNPs from the Affymetrix chip platform, 165 from the SNPlex platform, and 7 from the Sequenom platform (see Table, Supplemental Digital Content 1, http://links.lww.com/TP/A297) with a total of 2724 SNPs.
Data Analyses
We studied the association of SNPs with AR. Because we found a statistically different incidence of AR by site, the standard statistical methods included stratification by transplant center. The stratified analysis excludes the center with no AR event. For the final models, the P values for SNP association, below the FDR set at 10%, were considered statistically significant after accounting for multiple testing. Because standard statistical methods would not allow for analyzing SNPs at each center separately due to limited power, we also used several knowledge discovery methods to determine SNPs at each transplant center individually.
Standard Statistical Analysis of SNPs
Analysis was conducted using SAS version 9.1 (SAS Institute, Cary, NC, http://www.sas.com) using an additive genetic model. Separate Cox proportional hazards models were used to investigate the association of each SNP genotype with time to AR, adjusting for recipient race and stratifying by transplant center (20) . This analysis stratified by transplant center automatically excludes any center that does not have episodes of AR. Model selection was performed twice: once stratifying by transplant center and another time without (21) . Retained covariates from each model were combined to make a baseline model. Each SNP was added into the baseline model individually, and the model was stratified by the transplant center.
Knowledge Discovery Methods
To analyze SNPs at each center separately, we used knowledge discovery methods. We used three correlational-based feature selection in the Weka software suite of programs (Machine Learning Group, University of Waikato, New Zealand) (22) to select SNPs associated with AR at each of the transplant centers that had cases of AR. The correlation-based feature selections included a best-first search procedure (23) that was used to determine the SNPs eligible for the other two methods namely, a rule discovery tool named "JRip" (24) and decision trees were constructed with J48 (25) . The SNPs in rules that classified for presence of AR were extracted into the final feature set. The SNPs (nodes) of decision trees that resulted in positive outcome (presence of AR) were extracted to the final feature set. Each of the three knowledge discovery methods was conducted with 10-fold cross-validation with each fold preserving the distribution of the outcome of AR.
A final SNP set was created combining the SNPs found by the three knowledge discovery methods. Duplicates were removed from the final set. Then using a Cox proportional hazards model, we determined the association with AR for these SNPs, across all the transplant centers in the study.
Statistical Analysis of Biopsy Tubulitis Scores
To assess severity of AR, the study population was divided into groups: no biopsy, biopsy with t-score less than or equal to 1, and t-score more than or equal to 2. We then conducted a multinomial logistic regression analysis adjusted by clinical center.
